Molecular and cellular basis of cannabinoid and opioid interactions

Pharmacology Biochemistry and Behavior

Volumn 81, Issue 2 SPEC. ISS., 2005, Pages 360-368

  Viganò, Daniela ^a   Rubino, Tiziana ^a   Parolaro, Daniela ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Cannabinoids; Endogenous systems; Opioids; Signalling

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; ENDOCANNABINOID; MORPHINE; OPIATE; OPIATE PEPTIDE;

ANALGESIA; ANTINOCICEPTION; BRAIN DEPTH STIMULATION; CANNABIS ADDICTION; CONFERENCE PAPER; DRUG EFFECT; HUMAN; HYPOTHESIS; MOLECULAR MECHANICS; NEUROMODULATION; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR DENSITY; REWARD; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 20444399468     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.01.021     Document Type: Conference Paper

References (109)

1. M.E. Abood, K.E. Ditto, M.A. Noel, V.M. Showalter, and Q. Tao Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells Biochem Pharmacol 53 2 1997 207 214
2. M. Arnone, J. Maruani, F. Chaperon, M.H. Thiebot, M. Poncelet, and P. Soubrie Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors Psychopharmacology 132 1 1997 104 106
3. F. Berrendero, and R. Maldonado Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol Psychopharmacology 163 1 2002 111 117
4. H.N. Bhargava Inhibition of naloxone-induced withdrawal in morphine dependent mice by 1-trans-delta9-tetrahydrocannabinol Eur J Pharmacol 36 1 1976 259 262
5. H.N. Bhargava Time course of the effects of naturally occurring cannabinoids on morphine abstinence syndrome Pharmacol Biochem Behav 8 1 1978 7 11
6. A.S. Bloom, and W.L. Dewey A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse Psychopharmacology 57 3 1978 243 248
7. D. Braida, M. Pozzi, D. Parolaro, and M. Sala Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system Eur J Pharmacol 413 2001 227 234
8. C. Cadoni, A. Pisanu, M. Solinas, E. Acquas, and G. Di Chiara Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine Psychopharmacology 158 3 2001 259 266
9. S. Caille, and L.H. Parsons SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats Eur J Neurosci 18 11 2003 3145 3149
10. A. Castane, P. Robledo, A. Matifas, B.L. Kieffer, and R. Maldonado Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice Eur J Neurosci 17 1 2003 155 159
11. F. Chaperon, P. Soubrie, A.J. Puech, and M.H. Thiebot Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats Psychopharmacology 135 4 1998 324 332
12. J. Chen, W. Paredes, J.H. Lowinson, and E.L. Gardner Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex Eur J Pharmacol 190 1-2 1990 259 262
13. J.P. Chen, W. Paredes, J. Li, D. Smith, J. Lowinson, and E.L. Gardner Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis Psychopharmacology 102 2 1990 156 162
14. J.P. Chen, W. Paredes, J.H. Lowinson, and E.L. Gardner Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study Neurosci Lett 129 1 1991 136 180
15. J. Chen, R. Marmur, A. Pulles, W. Paredes, and E.L. Gardner Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient Brain Res 621 1 1993 65 70
16. S.R. Childers Opioid receptor-coupled second messenger systems Life Sci 48 21 1991 1991 2003
17. S.R. Childers, L. Fleming, C. Konkoy, D. Marckel, M. Pacheco, and T. Sexton Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain Ann N Y Acad Sci 654 1992 33 51
18. D.L. Cichewicz Synergistic interactions between cannabinoid and opioid analgesics Life Sci 74 11 2004 1317 1324
19. D.L. Cichewicz, and E.A. McCarthy Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration J Pharmacol Exp Ther 304 3 2003 1010 1015
20. D.L. Cichewicz, and S.P. Welch Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol J Pharmacol Exp Ther 305 3 2003 812 817
21. D.L. Cichewicz, Z.L. Martin, F.L. Smith, and S.P. Welch Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification J Pharmacol Exp Ther 289 2 1999 859 867
22. D.L. Cichewicz, V.L. Haller, and S.P. Welch Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine J Pharmacol Exp Ther 297 1 2001 121 127
23. J. Corchero, M.A. Avila, J.A. Fuentes, and J. Manzanares Delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat Life Sci 61 4 1997 39 43
24. J. Corchero, J.A. Fuentes, and J. Manzanares Delta 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus Eur J Pharmacol 323 2-3 1997 193 195
25. J. Corchero, J.M. Oliva, C. Garcia-Lecumberri, S. Martin, E. Ambrosio, and J. Manzanares Repeated administration with Delta9-tetrahydrocannabinol regulates mu-opioid receptor density in the rat brain J Psychopharmacol 18 1 2004 54 58
26. G. Cossu, C. Ledent, L. Fattore, A. Imperato, G.A. Bohme, and M. Parmentier Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse Behav Brain Res 118 1 2001 61 65
27. T.J. De Vries, J.R. Homberg, R. Binnekade, H. Raaso, and A.N. Schoffelmeer Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats Psychopharmacology (Berl) 168 1-2 2003 164 169
28. I. Del Arco, M. Navarro, A. Bilbao, B. Ferrer, D. Piomelli, and F. Rodriguez De Fonseca Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404 Eur J Pharmacol 454 1 2002 103 104
29. D.G. Deutsch, S.T. Glaser, J.M. Howell, J.S. Kunz, R.A. Puffenbarger, and C.J. Hillard The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase J Biol Chem 276 10 2001 6967 6973
30. W.A. Devane, J.W. Spain, C.J. Coscia, and A.C. Howlett An assessment of the role of opioid receptors in the response to cannabimimetic drugs J Neurochem 46 6 1986 1929 1935
31. R. Di Toro, G. Campana, V. Sciarretta, G. Murari, and S. Spampinato Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells Life Sci 63 14 1998 197 204
32. J.A. Dill, and A.C. Howlett Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs J Pharmacol Exp Ther 244 3 1988 1157 1163
33. L. Fattore, M.S. Spano, G. Cossu, S. Deiana, and W. Fratta Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats Eur J Neurosci 17 8 2003 1723 1726
34. J.J. Fernandez-Ruiz, R.M. Munoz, J. Romero, M.A. Villanua, A. Makriyannis, and J.A. Ramos Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics Biochem Pharmacol 53 12 1997 1919 1927
35. L.R. Gardell, M.H. Ossipov, T.W. Vanderah, J. Lai, and F. Porreca Dynorphin-independent spinal cannabinoid antinociception Pain 100 3 2002 243 248
36. E.L. Gardner, and J.H. Lowinson Marijuana's interaction with brain reward systems: update 1991 Pharmacol Biochem Behav 40 3 1991 571 580
37. E.L. Gardner, W. Paredes, D. Smith, A. Donner, C. Milling, and D. Cohen Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol Psychopharmacology 96 1 1988 142 144
38. S. Ghozland, H.W. Matthes, F. Simonin, D. Filliol, B.L. Kieffer, and R. Maldonado Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors J Neurosci 22 3 2002 1146 1154
39. 1 receptor binding and mRNA levels Drug Alcohol Depend 66 2002 77 84
40. S. Gonzalez, P.C. Schmid, J. Fernandez-Ruiz, R. Krebsbach, H.H. Schmid, and J.A. Ramos Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats Addict Biol 8 2 2003 159 166 [Jun]
41. M. Herkenham, A.B. Lynn, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J Neurosci 11 2 1991 563 583
42. B. Hine Morphine and delta 9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart-rate responses in the rat Psychopharmacology 87 1 1985 34 38
43. B. Hine, E. Friedman, M. Torrelio, and S. Gershon Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol Science 87 4175 1975 443 445
44. I.D. Hirschhorn, and J.A. Rosecrans Morphine and delta 9-tetrahydrocannabinol: tolerance to the stimulus effects Psychopharmacologia 36 3 1974 243 253
45. A.G. Hohmann, E.M. Briley, and M. Herkenham Pre-and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord Brain Res 822 1-2 1999 17 25
46. S.J. Houser, M. Eads, J.P. Embrey, and S.P. Welch Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide Brain Res 857 1-2 2000 337 342
47. A.C. Howlett Pharmacology of cannabinoid receptors Annu Rev Pharmacol Toxicol 35 1995 607 634
48. J Pharmacol Exp Ther 298 3 2001 1007 1014
49. Z. Justinova, G. Tanda, G.H. Redhi, and S.R. Goldberg Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys Psychopharmacology 169 2 2003 135 140 [Epub 2003 Jun 24]
50. Z. Justinova, G. Tanda, P. Munzar, and S.R. Goldberg The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys Psychopharmacology 173 1-2 2004 186 194
51. S. Kaymakcalan, I.H. Ayhan, and F.C. Tulunay Naloxone-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats Psychopharmacology 55 3 1977 243 249
52. T.C. Kirkham, and C.M. Williams Synergistic efects of opioid and cannabinoid antagonists on food intake Psychopharmacology 153 2 2001 267 270
53. S. Lamarque, K. Taghzouti, and H. Simon Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction Neuropharmacology 41 1 2001 118 129
54. P.Y. Law, J.E. Koehler, and H.H. Loh Comparison of opiate inhibition of adenylate cyclase activity in neuroblastoma N18tG2 and neuroblastoma × glioma NG108-15 hybrid cell lines Mol Pharmacol 21 2 1982 483 491
55. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.F. Aubert, and F. Beslot Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401 404
56. A.H. Lichtman, S.A. Cook, and B.R. Martin Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement J Pharmacol Exp Ther 276 2 1996 585 593
57. A.H. Lichtman, S.M. Sheikh, H.H. Loh, and B.R. Martin Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)- tetrahydrocannabinol and morphine-dependent mice J Pharmacol Exp Ther 298 3 2001 1007 1014
58. P. Mailleux, and J.J. Vanderhaeghen Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry Neuroscience 48 3 1992 655 668
59. R. Maldonado, and O. Valverde Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses Eur Neuropsychopharmacol 13 6 2003 401 410
60. A. Mansour, H. Khachaturian, M.E. Lewis, H. Akil, and S.J. Watson Anatomy of CNS opioid receptors Trends Neurosci 11 7 1988 308 314
61. A. Mansour, C.A. Fox, H. Akil, and S.J. Watson Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications Trends Neurosci 18 1 1995 22 29
62. J. Manzanares, J. Corchero, J. Romero, J.J. Fernandez-Ruiz, J.A. Ramos, and J.A. Fuentes Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain Brain Res Mol Brain Res 55 1 1998 126 132
63. J. Manzanares, J. Corchero, J. Romero, J.J. Fernandez-Ruiz, A. Ramos, and J.A. Fuentes Pharmacological and biochemical interactions between opioids and cannabinoids Trends Pharmacol Sci 20 1999 287 294
64. J. Mao, D.D. Price, J. Lu, L. Keniston, and D.J. Mayer Two distinctive antinociceptive systems in rats with pathological pain Neurosci Lett 280 1 2000 13 16
65. S. Marin, E. Marco, M. Biscaia, B. Fernandez, M. Rubio, and C. Guaza Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats Pharmacol Biochem Behav 74 3 2003 649 656
66. M. Martin, C. Ledent, M. Parmentier, R. Maldonado, and O. Valverde Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice Eur J Neurosci 2 11 2000 4038 4046
67. M. Mas-Nieto, B. Pommier, E.T. Tzavara, A. Caneparo, S. Da Nascimento, and G. Le Fur Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction Br J Pharmacol 132 8 2001 1809 1816
68. D.J. Mason Jr., J. Lowe, and S.P. Welch Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception Eur J Pharmacol 378 3 1999 237 248
69. P. Massi, A. Vaccani, S. Romorini, and D. Parolaro Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosoppressive and analgesic effects J Neuroimmunol 117 1-2 2001 116 124
70. P. Massi, A. Vaccani, T. Rubino, and D. Parolaro Cannabinoids and opioids share cAMP pathway in rat splenocytes J Neuroimmunol 145 1-2 2003 46 54
71. M. Navarro, J.J. Fernandez-Ruiz, R. de Miguel, M.L. Hernandez, M. Cebeira, and JA. Ramos An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity Behav Brain Res 57 1 1993 37 46
72. M. Navarro, J. Chowen, A. Rocio, M. Carrera, I. del Arco, and M.A. Villanua CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats Neuroreport 9 15 1998 3397 3402
73. M. Navarro, M.N. Carrera, W. Fratta, O. Valverde, G. Cossu, and L. Fattore Functional interaction between opioid and cannabinoid receptors in drug self-administration J Neurosci 21 2001 5344 5350
74. a giornata italiana endocannabinoidi. Università degli Studi di Salerno, Fisciano (SA); 2003 Dec. personal comunication.
75. F.E. Pontieri, P. Monnazzi, A. Scontrini, F.R. Buttarelli, and F.R. Patacchioli Behavioral sensitization to heroin by cannabinoid pretreatment in the rat Eur J Pharmacol 421 3 2001 R1 R3
76. F.E. Pontieri, P. Monnazzi, A. Scontrini, F.R. Buttarelli, and F.R. Patacchioli Behavioral sensitization to WIN55212.2 in rats pretreated with heroin Brain Res 898 1 2001 178 180
77. G. Pugh Jr., D.J. Mason Jr., V. Combs, and S.P. Welch Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord J Pharmacol Exp Ther 281 2 1997 730 737
78. I. Reche, J.A. Fuentes, and M. Ruiz-Gayo Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu-and kappa-opioid receptors Eur J Pharmacol 318 1 1996 11 16
79. I. Reche, J.A. Fuentes, and M. Ruiz-Gayo A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice Eur J Pharmacol 301 1-3 1996 75 81
80. I. Reche, M. Ruiz-Gayo, and J.A. Fuentes Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice Neuropharmacology 37 2 1998 215 222
81. O.V. Rice, N. Gordon, and A.N. Gifford Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice Brain Res 945 1 2002 135 138
82. J.J. Rodriguez, K. Mackie, and V.M. Pickel Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus J Neurosci 21 3 2001 823 833
83. J. Romero, T. Wenger, R. de Miguel, J.A. Ramos, and J.J. Fernandez-Ruiz Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation Life Sci 63 5 1998 351 356
84. 35S]GTPγS binding in morphine-dependent mice Drug Alcohol Depend 50 1998 241 249
85. T. Rubino, L. Tizzoni, D. Viganò, P. Massi, and D. Parolaro Modulation of rat brain cannabinoid receptors after chronic morphine treatment Neuroreport 8 1997 3219 3223
86. T. Rubino, P. Massi, D. Viganò, D. Fuzio, and D. Parolaro Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome Life Sci 66 22 2000 2213 2219
87. C. Salio, J. Fischer, M.F. Franzoni, K. Mackie, T. Kaneko, and M. Conrath CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn Neuroreport 12 17 2001 3689 3692
88. E. Schlicker, and M. Kathmann Modulation of transmitter release via presynaptic cannabinoid receptors Trends Pharmacol Sci 22 11 2001 565 572
89. M. Shapira, M. Gafni, and Y. Sarne Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cells Brain Res 806 1998 26 35
90. M. Shapira, Z. Vogel, and Y. Sarne Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors Cell Mol Neurobiol 20 3 2000 291 304
91. M. Shapira, M. Gafni, and Y. Sarne Long-term interactions between opioid and cannabinoid agonists at the cellular level: cross-desensitization and downregulation Brain Res 960 1-2 2003 190 200
92. P.B. Smith, S.P. Welch, and B.R. Martin Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice J Pharmacol Exp Ther 268 3 1994 1381 1387
93. F.L. Smith, D. Cichewicz, Z.L. Martin, and S.P. Welch The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol Pharmacol Biochem Behav 60 2 1998 559 566
94. M. Solinas, L.V. Panlilio, K. Antoniou, L.A. Pappas, and S.R. Goldberg The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats J Pharmacol Exp Ther 306 1 2003 93 102
95. G. Tanda, F.E. Pontieri, and G. Di Chiara Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu opioid receptor mechanism Science 276 5321 1997 2048 2050
96. G. Tanda, P. Munzar, and S.R. Goldberg Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys Nat Neurosci 3 11 2000 1073 1074
97. 9-tetrahydrocannabinol in mice Eur J Pharmacol 260 1994 5 13
98. O. Valverde, C. Ledent, F. Beslot, M. Parmentier, and B.P. Roques Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors Eur J Neurosci 12 2 2000 533 539
99. O. Valverde, R. Maldonado, E. Valjent, A.M. Zimmer, and A. Zimmer Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice J Neurosci 20 24 2000 9284 9289
100. O. Valverde, F. Noble, F. Beslot, V. Dauge, M.C. Fournie-Zaluski, and B.P. Roques Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enklephalins: reduction in morphine withdrawal syndrome without change in rewarding effect Eur J Neurosci 13 2001 1816 1824
101. S.A. Varvel, D.L. Cichewicz, and A.H. Lichtman Interactions between cannabionoids and opioids Tibor Wenger Recent Advances in Pharmacology and Physiology of Cannabinoids 2004 Research Signpost Trivandrum-695 023 Kerala, India 157 182
102. G. Vela, M. Ruiz-Gayo, and J.A. Fuentes Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine Neuropharmacology 34 6 1995 665 668
103. D. Viganò, M. Grazia Cascio, T. Rubino, F. Fezza, A. Vaccani, and V. Di Marzo Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain Neuropsychopharmacology 28 6 2003 1160 1167
104. S.P. Welch Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice J Pharmacol Exp Ther 265 2 1993 633 640
105. S.P. Welch Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems Drug Alcohol Depend 45 1-2 1997 39 45
106. S. Welch, and M. Eads Synergistic interactions of endogenous opioids and cannabinoid systems Brain Res 848 1999 183 190
107. C.M. Williams, and T.C. Kirkham Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine Pharmacol Biochem Behav 71 1-2 2002 333 340 [Jan-Feb]
108. T. Yamaguchi, Y. Hagiwara, H. Tanaka, T. Sugiura, K. Waku, and Y. Shoyama Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone- precipitated withdrawal signs in morphine-dependent mice Brain Res 909 2001 121 126
109. A. Zimmer, E. Valjent, M. Konig, A.M. Zimmer, P. Robledo, and H. Hahn Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice J Neurosci 21 23 2001 9499 9505